Combined use of the ketogenic diet and vagus nerve stimulation in pediatric drug-resistant epilepsy
© 2020 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy..
Objective: Patients with drug-resistant epilepsy (DRE) pose considerable management challenges for patients, their families, and providers. Both the vagus nerve stimulator (VNS) and the ketogenic diet (KD) have been shown to be safe and effective in treating DRE. Nevertheless, information is lacking regarding treatment with combination of both modalities. This study reports the efficacy and tolerability of combining VNS and KD in a pediatric cohort with intractable epilepsy.
Methods: This is a retrospective review of 33 patients (0-17 years) with DRE treated with VNS and KD at a single pediatric level IV epilepsy center. We compared seizure reduction rates for each patient at baseline and at every clinic visit for 24 months after adding the second nonpharmacological therapy. The frequency of adverse events on the combined therapy was collected to assess safety and tolerability.
Results: There were a total of 170 visits for all patients while on the combined therapy. At 88% (95% CI: 83%-93%) of the visits, patients reported some reduction in seizure frequency. The proportion of patients reporting a greater than 50% seizure reduction over all visits was 62% (95% CI: 55%-69%). The proportion of a patient's visits with at least a greater than 50% reduction in seizure frequency had a median of 71% (IQR 33%-100%). Continued improvement was seen over time of combined treatment; for every one-unit time unit change (one month), there was a 6% increase in the odds of having a reduction in seizure frequency of >50% (OR = 1.06, 95% CI: 1.01-1.11).
Significance: This study shows that combining the VNS and KD in patients with drug-resistant epilepsy is well tolerated and reduces seizure frequency more than either one modality used alone and that the benefits in terms of seizure reduction continue to increase with the length of treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Epilepsia open - 6(2021), 1 vom: 02. März, Seite 112-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdelmoity, Ayman T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epilepsy surgery |
|---|
| Anmerkungen: |
Date Completed 19.10.2021 Date Revised 31.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1002/epi4.12453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322388864 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322388864 | ||
| 003 | DE-627 | ||
| 005 | 20240331232810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/epi4.12453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM322388864 | ||
| 035 | |a (NLM)33681654 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdelmoity, Ayman T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined use of the ketogenic diet and vagus nerve stimulation in pediatric drug-resistant epilepsy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2021 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. | ||
| 520 | |a Objective: Patients with drug-resistant epilepsy (DRE) pose considerable management challenges for patients, their families, and providers. Both the vagus nerve stimulator (VNS) and the ketogenic diet (KD) have been shown to be safe and effective in treating DRE. Nevertheless, information is lacking regarding treatment with combination of both modalities. This study reports the efficacy and tolerability of combining VNS and KD in a pediatric cohort with intractable epilepsy | ||
| 520 | |a Methods: This is a retrospective review of 33 patients (0-17 years) with DRE treated with VNS and KD at a single pediatric level IV epilepsy center. We compared seizure reduction rates for each patient at baseline and at every clinic visit for 24 months after adding the second nonpharmacological therapy. The frequency of adverse events on the combined therapy was collected to assess safety and tolerability | ||
| 520 | |a Results: There were a total of 170 visits for all patients while on the combined therapy. At 88% (95% CI: 83%-93%) of the visits, patients reported some reduction in seizure frequency. The proportion of patients reporting a greater than 50% seizure reduction over all visits was 62% (95% CI: 55%-69%). The proportion of a patient's visits with at least a greater than 50% reduction in seizure frequency had a median of 71% (IQR 33%-100%). Continued improvement was seen over time of combined treatment; for every one-unit time unit change (one month), there was a 6% increase in the odds of having a reduction in seizure frequency of >50% (OR = 1.06, 95% CI: 1.01-1.11) | ||
| 520 | |a Significance: This study shows that combining the VNS and KD in patients with drug-resistant epilepsy is well tolerated and reduces seizure frequency more than either one modality used alone and that the benefits in terms of seizure reduction continue to increase with the length of treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a epilepsy surgery | |
| 650 | 4 | |a neuromodulation | |
| 650 | 4 | |a safety & efficacy | |
| 650 | 4 | |a seizure control | |
| 700 | 1 | |a Le Pichon, Jean-Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmoity, Sherouk A |e verfasserin |4 aut | |
| 700 | 1 | |a Sherman, Ashley K |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Ara S |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmoity, Ahmed T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epilepsia open |d 2016 |g 6(2021), 1 vom: 02. März, Seite 112-119 |w (DE-627)NLM271009934 |x 2470-9239 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:1 |g day:02 |g month:03 |g pages:112-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/epi4.12453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 1 |b 02 |c 03 |h 112-119 | ||